Your browser doesn't support javascript.
loading
The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of "Tail Wags Dog" Experiments.
Wang, Meining; Irvin, Thomas C; Herdman, Christine A; Hanna, Ramsey D; Hassan, Sergio A; Lee, Yong-Sok; Kaska, Sophia; Crowley, Rachel Saylor; Prisinzano, Thomas E; Withey, Sarah L; Paronis, Carol A; Bergman, Jack; Inan, Saadet; Geller, Ellen B; Adler, Martin W; Kopajtic, Theresa A; Katz, Jonathan L; Chadderdon, Aaron M; Traynor, John R; Jacobson, Arthur E; Rice, Kenner C.
Afiliación
  • Wang M; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
  • Irvin TC; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
  • Herdman CA; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
  • Hanna RD; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
  • Hassan SA; Department of Health and Human Services, Center for Molecular Modeling, Office of Intramural Research, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lee YS; Department of Health and Human Services, Center for Molecular Modeling, Office of Intramural Research, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kaska S; Department of Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS 66045-7582, USA.
  • Crowley RS; Department of Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS 66045-7582, USA.
  • Prisinzano TE; Department of Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS 66045-7582, USA.
  • Withey SL; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA.
  • Paronis CA; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA.
  • Bergman J; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA.
  • Inan S; Center for Substance Abuse Research, Lewis Katz School of Medicine of Temple University, 3500 N. Broad St., Philadelphia, PA 19140, USA.
  • Geller EB; Center for Substance Abuse Research, Lewis Katz School of Medicine of Temple University, 3500 N. Broad St., Philadelphia, PA 19140, USA.
  • Adler MW; Center for Substance Abuse Research, Lewis Katz School of Medicine of Temple University, 3500 N. Broad St., Philadelphia, PA 19140, USA.
  • Kopajtic TA; Department of Health and Human Services, Psychobiology Section, Molecular Neuropsychiatry Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
  • Katz JL; Department of Health and Human Services, Psychobiology Section, Molecular Neuropsychiatry Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
  • Chadderdon AM; Department of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Traynor JR; Department of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Jacobson AE; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
  • Rice KC; Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
Molecules ; 25(11)2020 Jun 06.
Article en En | MEDLINE | ID: mdl-32517185
ABSTRACT
(-)-N-Phenethyl analogs of optically pure N-norhydromorphone were synthesized and pharmacologically evaluated in several in vitro assays (opioid receptor binding, stimulation of [35S]GTPγS binding, forskolin-induced cAMP accumulation assay, and MOR-mediated ß-arrestin recruitment assays). "Body" and "tail" interactions with opioid receptors (a subset of Portoghese's message-address theory) were used for molecular modeling and simulations, where the "address" can be considered the "body" of the hydromorphone molecule and the "message" delivered by the substituent (tail) on the aromatic ring of the N-phenethyl moiety. One compound, N-p-chloro-phenethynorhydromorphone ((7aR,12bS)-3-(4-chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one, 2i), was found to have nanomolar binding affinity at MOR and DOR. It was a potent partial agonist at MOR and a full potent agonist at DOR with a δ/µ potency ratio of 1.2 in the ([35S]GTPγS) assay. Bifunctional opioids that interact with MOR and DOR, the latter as agonists or antagonists, have been reported to have fewer side-effects than MOR agonists. The p-chlorophenethyl compound 2i was evaluated for its effect on respiration in both mice and squirrel monkeys. Compound 2i did not depress respiration (using normal air) in mice or squirrel monkeys. However, under conditions of hypercapnia (using air mixed with 5% CO2), respiration was depressed in squirrel monkeys.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Opioides delta / Receptores Opioides mu / Hidromorfona / Hipercapnia Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Molecules Asunto de la revista: BIOLOGIA Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Opioides delta / Receptores Opioides mu / Hidromorfona / Hipercapnia Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Molecules Asunto de la revista: BIOLOGIA Año: 2020 Tipo del documento: Article
...